| Recruiting | 1 | 715 | Japan | AB122, TAS-116, TAS-120, TAS-115, TAS-102, Ramucirumab, Bevacizumab | Taiho Pharmaceutical Co., Ltd. | Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma | 05/26 | 05/26 | | |
POTENTIATE, NCT05827614: Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications |
|
|
| Recruiting | 1 | 150 | US | BBI-355, Erlotinib, Futibatinib | Boundless Bio | Non-small Cell Lung Cancer, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer, Gastric Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Liposarcoma | 09/26 | 09/27 | | |
